KEYNOTE-890

GPTKB entity

Statements (19)
Predicate Object
gptkbp:instance_of gptkb:legal_case
gptkbp:clinical_trial NC T04212345
gptkbp:criteria adults aged 18 and older
previous treatment with anti-PD-1 therapy
gptkbp:end_date 2023-12-31
https://www.w3.org/2000/01/rdf-schema#label KEYNOTE-890
gptkbp:is_tested_for Phase 2
gptkbp:launch_date 2020-01-01
gptkbp:location multiple sites
gptkbp:participants overall response rate
progression-free survival
gptkbp:result not yet published
gptkbp:social_responsibility gptkb:healthcare_organization
gptkbp:sponsor gptkb:Merck_&_Co.
gptkbp:status ongoing
gptkbp:student_enrollment approximately 200 participants
gptkbp:treatment gptkb:Pembrolizumab
gptkbp:bfsParent gptkb:Onco_Sec_Medical
gptkbp:bfsLayer 5